|
JP7451419B2
(ja)
|
2018-10-26 |
2024-03-18 |
大鵬薬品工業株式会社 |
新規なインダゾール化合物又はその塩
|
|
US20220227738A1
(en)
*
|
2019-05-20 |
2022-07-21 |
California Institute Of Technology |
Kras g12c inhibitors and uses thereof
|
|
CN112552294B
(zh)
*
|
2019-09-10 |
2023-12-19 |
上海翰森生物医药科技有限公司 |
含哌嗪杂环类衍生物抑制剂、其制备方法和应用
|
|
CN112047937B
(zh)
*
|
2019-06-06 |
2023-04-07 |
劲方医药科技(上海)有限公司 |
四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
|
|
CN110256421A
(zh)
*
|
2019-06-26 |
2019-09-20 |
微境生物医药科技(上海)有限公司 |
Kras-g12c抑制剂
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN114269735B
(zh)
*
|
2019-08-26 |
2024-02-23 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
CR20220230A
(es)
|
2019-10-28 |
2022-06-15 |
Merck Sharp & Dohme |
Inhibidores de pequeñas moléculas de mutante g12c de kras
|
|
EP4054719B1
(en)
|
2019-11-04 |
2026-02-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
KR20220109407A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
JP7823816B2
(ja)
|
2019-11-04 |
2026-03-04 |
レヴォリューション・メディスンズ，インコーポレイテッド |
Ｒａｓ阻害剤
|
|
WO2021093758A1
(zh)
*
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CA3232127A1
(en)
*
|
2020-03-12 |
2021-09-16 |
D3 Bio (Wuxi) Co., Ltd. |
Pyrimidoheterocyclic compounds and application thereof
|
|
JP7461499B2
(ja)
*
|
2020-04-03 |
2024-04-03 |
メッドシャイン ディスカバリー インコーポレイテッド |
オクタヒドロピラジノジアザナフチリジンジオン化合物
|
|
WO2021216770A1
(en)
*
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
KR20230019855A
(ko)
*
|
2020-06-04 |
2023-02-09 |
안텐진 디스커버리 리미티드 |
Kras g12c 단백질의 억제제 및 그의 용도
|
|
CA3183032A1
(en)
|
2020-06-18 |
2021-12-23 |
Mallika Singh |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
|
WO2022040469A1
(en)
|
2020-08-19 |
2022-02-24 |
The Trustees Of The Stevens Institute Of Technology |
Spiro compounds as kras inhibitors
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
|
US12162893B2
(en)
|
2020-09-23 |
2024-12-10 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20220112204A1
(en)
*
|
2020-10-14 |
2022-04-14 |
Accutar Biotechnology Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
|
TW202231273A
(zh)
*
|
2020-10-21 |
2022-08-16 |
美商博奥阿迪斯有限公司 |
作為ras抑制劑的化合物及其用途
|
|
WO2022109485A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
WO2022109487A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
WO2022115439A1
(en)
*
|
2020-11-25 |
2022-06-02 |
California Institute Of Technology |
Kras g12c inhibitors and uses thereof
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN114716436A
(zh)
*
|
2021-01-04 |
2022-07-08 |
广州百霆医药科技有限公司 |
Kras g12c突变抑制剂及其用途
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022156761A1
(en)
*
|
2021-01-21 |
2022-07-28 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Spirocyclic indenes
|
|
MX2023009037A
(es)
*
|
2021-02-01 |
2023-08-10 |
Medshine Discovery Inc |
Compuesto de pirimidopirano.
|
|
WO2022171013A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
四氢喹唑啉类化合物
|
|
CN116801883A
(zh)
*
|
2021-03-18 |
2023-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
IL308193A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors
|
|
WO2022240971A2
(en)
*
|
2021-05-11 |
2022-11-17 |
1200 Pharma Llc |
Kras g12d inhibitors and uses thereof
|
|
US20240417408A1
(en)
*
|
2021-05-28 |
2024-12-19 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2022344134A1
(en)
|
2021-09-09 |
2024-03-21 |
Mirati Therapeutics, Inc. |
Processes and intermediates for synthesis of adagrasib
|
|
TWI820901B
(zh)
*
|
2021-09-10 |
2023-11-01 |
大陸商德昇濟醫藥（無錫）有限公司 |
嘧啶並雜環類化合物的晶型及其製備方法
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
JP2025500878A
(ja)
|
2021-12-17 |
2025-01-15 |
ジェンザイム・コーポレーション |
Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
|
|
CN114409653A
(zh)
*
|
2021-12-31 |
2022-04-29 |
苏州闻天医药科技有限公司 |
一种桥环并嘧啶并环类化合物及其用途
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4563580A4
(en)
|
2022-07-27 |
2025-10-29 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Fused cyclic compound, its preparation process and its medicinal application
|
|
WO2024040131A1
(en)
|
2022-08-17 |
2024-02-22 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
PE20260039A1
(es)
|
2023-04-07 |
2026-01-09 |
Revolution Medicines Inc |
Inhibidores macrociclicos de ras
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
TW202500126A
(zh)
|
2023-05-24 |
2025-01-01 |
美商金橘生物科技公司 |
雜環化合物及其用途
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025064848A1
(en)
|
2023-09-21 |
2025-03-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyridine kras inhibitors
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
TW202545999A
(zh)
|
2024-02-06 |
2025-12-01 |
美商金橘生物科技公司 |
雜環綴合物及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|